A prospective, single-centre, observational, real world, post-marketing surveillance to evaluate safety and performance of the BioMimeâ?¢ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions

Trial Profile

A prospective, single-centre, observational, real world, post-marketing surveillance to evaluate safety and performance of the BioMimeâ?¢ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Meril Life Sciences
  • Most Recent Events

    • 11 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top